| 1. |
|
|
| 2. |
- Aili, Katarina, PhD, 1980-, et al.
(author)
-
Health-related quality of life in adults treated for paediatric acute lymphoblastic leukaemia: a cross-sectional and longitudinal cohort study
- 2022
-
In: Bmj Open. - London : BMJ. - 2044-6055. ; 12:1
-
Journal article (peer-reviewed)abstract
- Introduction Acute lymphoblastic leukaemia (ALL) is the most common form of cancer in children. Although treatment methods have improved and resulted in significant improvement of survival and reduction in late effects and late mortality risk, the health-related quality of life (HRQOL) of survivors might be affected. To introduce new interventions in clinical practice with the potential to support positive HRQOL outcomes, more knowledge is needed on how HRQOL in this group is constructed and stimulated. The purpose of this study is to investigate how HRQOL is affected in adults treated for paediatric ALL, in a long-term perspective and possible factors influencing this relationship. Methods and analysis This cohort of young adult ALL survivors allows for investigations of factors influencing HRQOL outcomes on a national level. Eligible participants are obtained from the Swedish Childhood Cancer quality registry. Data collection includes both a follow-up of data collected in 2012 (n=224) and recruitment of new eligible participants to the cohort (n=601). The cohort will cover survivors of paediatric ALL, diagnosed between 1985 and 2007, at an age between 0 and 15 years. Data will be collected using validated, multidimensional, self-administered instruments, designed to measure HRQOL (SF-36), social support, sense of coherence and resilience. Ethics and dissemination The study will be carried out in accordance with the ethics permit obtained from the Swedish ethics review authority (Dnr 2019-05181). Dissemination of study results will take place through research articles and reports to the national patient organisation and the national network for consultancy nurses for this target group and to the working group for the Swedish national long-term care programme for childhood cancer. Results will also reach practical application within the follow-up clinic for adult childhood cancer survivors at Sahlgrenska Hospital in Gothenburg.
|
|
| 3. |
- Bronge, Mattias, et al.
(author)
-
Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis
- 2022
-
In: Science Advances. - : American Association for the Advancement of Science (AAAS). - 2375-2548. ; 8:17
-
Journal article (peer-reviewed)abstract
- Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), in which pathological T cells, likely autoimmune, play a key role. Despite its central importance, the autoantigen repertoire remains largely uncharacterized. Using a novel in vitro antigen delivery method combined with the Human Protein Atlas library, we screened for T cell autoreactivity against 63 CNS-expressed proteins. We identified four previously unreported autoantigens in MS: fatty acid-binding protein 7, prokineticin-2, reticulon-3, and synaptosomal-associated protein 91, which were verified to induce interferon-gamma responses in MS in two cohorts. Autoreactive profiles were heterogeneous, and reactivity to several autoantigens was MS-selective. Autoreactive T cells were predominantly CD4(+) and human leukocyte antigen-DR restricted. Mouse immunization induced antigen-specific responses and CNS leukocyte infiltration. This represents one of the largest systematic efforts to date in the search for MS autoantigens, demonstrates the heterogeneity of autoreactive profiles, and highlights promising targets for future diagnostic tools and immunomodulatory therapies in MS.
|
|
| 4. |
- Cortinovis, Chiara, et al.
(author)
-
Assessing Potential for and Benefits of Scaling up Nature-Based Solutions in Malmö
- 2022
-
In: Innovation in Urban and Regional Planning - Proceedings of the 11th INPUT Conference. - Cham : Springer International Publishing. - 2366-2565 .- 2366-2557. - 9783030969844 ; 242 LNCE, s. 3-11
-
Conference paper (peer-reviewed)abstract
- While many projects have demonstrated the potential of single Nature-based Solutions (NbS) to contribute to urban climate change adaptation, the challenge now lies in moving from demonstration projects to a full-scale deployment. The aim of this research is to assess the potential for a full-scale implementation of NbS in Malmö (Sweden), and the expected benefits and co-benefits. We developed six scenarios that simulate the current condition, the full-scale implementation of different NbS strategies (i.e., installing extensive green roofs, planting street trees, desealing parking areas, and enhancing vegetation in urban parks), and a combination of them. Then, we assessed the scenarios in terms of heat mitigation, stormwater regulation, carbon storage, biodiversity potential, and overall greenness, using a combination of spatially-explicit methods. Overall, the research reveals that the impacts of scaling up NbS depends on two factors: i) the existing potential to integrate NbS in the urban fabric, and ii) the capacity of each NbS type to deliver benefits in certain conditions.
|
|
| 5. |
- Cortinovis, Chiara, et al.
(author)
-
Scaling up nature-based solutions for climate-change adaptation : Potential and benefits in three European cities
- 2022
-
In: Urban Forestry and Urban Greening. - : Elsevier BV. - 1618-8667. ; 67
-
Journal article (peer-reviewed)abstract
- Many exemplary projects have demonstrated that Nature-based Solutions (NBS) can contribute to climate change adaptation, but now the challenge is to scale up their use. Setting realistic policy goals requires knowing the amount of different NBS types that can fit in the urban space and the benefits that can be expected. This research aims to assess the potential for a full-scale implementation of NBS for climate-change adaptation in European cities, the expected benefits and co-benefits, and how these quantities relate to the urban structure of the cities. We selected three case studies: Barcelona (Spain), Malmö (Sweden), and Utrecht (the Netherlands), and developed six scenarios that simulate the current condition, the full-scale implementation of different NBS strategies (i.e., installing green roofs, de-sealing parking areas, enhancing vegetation in urban parks, and planting street trees), and a combination of them. Then we applied spatially-explicit methods to assess, for each scenario, two climate change-related benefits, i.e. heat mitigation and stormwater regulation, and three co-benefits, namely carbon storage, biodiversity potential, and overall greenness. Finally, by breaking down the results per land use class, we investigated how the potential and benefits vary depending on the urban form. Most scenarios provide multiple benefits, but each one is characterized by a specific mix. In all cities, a full-scale deployment of green roofs shows the greatest potential to reduce runoff and increase biodiversity, while tree planting -either along streets or in urban parks– produces the greatest impact on heat mitigation and greenness. However, these results entail interventions of different size and in different locations. Planting street trees maximizes interventions in residential areas, but key opportunities for integrating most NBS types also lie in commercial and industrial areas. The results on the pros and cons of each scenario can support policy-makers in designing targeted NBS strategies for climate change adaptation.
|
|
| 6. |
- Deland, Lily, et al.
(author)
-
Novel TPR::ROS1 Fusion Gene Activates MAPK, PI3K and JAK/STAT Signaling in an Infant-type Pediatric Glioma.
- 2022
-
In: Cancer genomics & proteomics. - : Anticancer Research USA Inc.. - 1109-6535 .- 1790-6245. ; 19:6, s. 711-726
-
Journal article (peer-reviewed)abstract
- Although fusion genes involving the proto-oncogene receptor tyrosine kinase ROS1 are rare in pediatric glioma, targeted therapies with small inhibitors are increasingly being approved for histology-agnostic fusion-positive solid tumors.Here, we present a 16-month-old boy, with a brain tumor in the third ventricle. The patient underwent complete resection but relapsed two years after diagnosis and underwent a second operation. The tumor was initially classified as a low-grade glioma (WHO grade 2); however, methylation profiling suggested the newly WHO-recognized type: infant-type hemispheric glioma. To further refine the molecular background, and search for druggable targets, whole genome (WGS) and whole transcriptome (RNA-Seq) sequencing was performed.Concomitant WGS and RNA-Seq analysis revealed several segmental gains and losses resulting in complex structural rearrangements and fusion genes. Among the top-candidates was a novel TPR::ROS1 fusion, for which only the 3' end of ROS1 was expressed in tumor tissue, indicating that wild type ROS1 is not normally expressed in the tissue of origin. Functional analysis by Western blot on protein lysates from transiently transfected HEK293 cells showed the TPR::ROS1 fusion gene to activate the MAPK-, PI3K- and JAK/STAT- pathways through increased phosphorylation of ERK, AKT, STAT and S6. The downstream pathway activation was also confirmed by immunohistochemistry on tumor tissue slides from the patient.We have mapped the activated oncogenic pathways of a novel ROS1-fusion gene and broadened the knowledge of the newly recognized infant-type glioma subtype. The finding facilitates suitable targeted therapies for the patient in case of relapse.
|
|
| 7. |
|
|
| 8. |
- Hedlund, Katarina, et al.
(author)
-
Utmaningar och möjligheter
- 2022
-
In: Markanvändning för en klimatpositiv framtid : En rapport om utmaningar och möjligheter i Skåne - En rapport om utmaningar och möjligheter i Skåne. - 9789198434996 - 9789198434989 ; , s. 48-60
-
Book chapter (other academic/artistic)
|
|
| 9. |
|
|
| 10. |
- Humphries, Sophia, et al.
(author)
-
Association between β-blocker dose and quality of life after myocardial infarction : a real-world Swedish register-linked study
- 2022
-
In: European Heart Journal. - : Oxford University Press. - 2048-8726 .- 2048-8734. ; 11:6, s. 491-500
-
Journal article (peer-reviewed)abstract
- Background β-blockers are routinely administered to patients following myocardial infarction (MI), yet their potential effect on health-related quality of life (HRQoL) is not entirely understood. We investigated the relationship between two different doses of β-blockers with HRQoL following MI.Methods and results This nationwide observational study used Swedish national registries to collate sociodemographic, clinical, medication, and HRQoL {the latter operationalized using EuroQol [European Quality of Life Five Dimensions Questionnaire (EQ-5D)]}. Estimates at 6–10 weeks and 12–14 months post-MI follow-up from pooled linear and logistic models were calculated after multiple imputation. We identified 35 612 patients with first-time MI, discharged with β-blockers, and enrolled in cardiac rehabilitation between 2006 and 2015. Upon discharge, patients were either dispensed <50% [24 082 (67.6%)] or ≥50% [11 530 (32.4%)] of the target dosage, as defined in previous trials. After adjusting for pre-defined covariates, neither the EQ-5D Index nor the Emotional Distress items were statistically different between groups. The EQ-VAS score was significantly lower in patients treated with ≥50% target β-blocker dose than those treated with <50% of the target dose [−0.87 [−1.23, −0.46], P < .001]. Results were similar at the 12-month follow-up and across sub-groups separated by sex and age.Conclusion No difference in HRQoL was found among patients taking <50% vs. ≥50% of the target β-blocker dose, except for the EQ-VAS in which higher scores were reported in those taking a lower dose. The clinical meaningfulness of this statistical significance is likely low.
|
|
